Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954316 · ClinicalTrials.gov registry record · Phase 1
A Study of CFI-400945 Fumarate in Patients With Advanced Cancer
A Phase 1 study, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01954316 is a Phase 1 study that has completed, run by University Health Network, Toronto. The registered enrollment target is 46 participants.
The verdict
NCT01954316, a Phase 1 study, has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a phase 1 study to test different doses of a new investigational drug called CFI-400945 to see which dose is safer in people. This study will also look at the safety of CFI-400945 and to study its effects on patients with advanced cancers. This drug has been tested in animals but not yet in people. CFI-400945 is an oral (taken by mouth) drug that works by blocking polo-like kinase 4 (PLK4) from working. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to lead to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors growing or shrink them.
Interventions
- DRUG CFI-400945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2014-03 |
| Est. Completion | 2021-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954316
The ClinicalTrials.gov registry entry for NCT01954316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CFI-400945 is the first listed.
NCT01954316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01954316 about?
NCT01954316 is a clinical study titled "A Study of CFI-400945 Fumarate in Patients With Advanced Cancer". This is a phase 1 study to test different doses of a new investigational drug called CFI-400945 to see which dose is safer in people. This study will also look at the safety of CFI-400945 and to study its effects on patients with advanced cancers. This drug has been tested in animals but not yet in ...
What is the current status of trial NCT01954316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2014-03. Estimated completion is 2021-07-22.
What interventions are being tested in trial NCT01954316?
The interventions under investigation include: CFI-400945 (DRUG).
Who is sponsoring clinical trial NCT01954316?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.